The Problem is complex but our Mission is simple.
There are 6 million new canine cancer diagnoses made every year. An unknown multiple of thousands of dogs have been diagnosed with Transitional Cell Carcinoma (TCC), and every year hundreds more are diagnosed and treated. However, there has been only a handful of published controlled clinical trials of canines with TCC.
Yet dogs are continuously diagnosed, and undergo various treatment regimens, surgical procedures and dietary regimens.
Those regimens and outcomes are not being captured, and we aim to do just that.
Why? Because that data could hold the key to better treatment and improved outcomes.
And not just for canines.
The Canine Genome Sequencing Project at the Broad Institute mapped the genome of a dog named Tasha and discovered that many of the same genes involved in dog cancers are identical to that of humans.
And canine TCC is unique in that regard. The BRAF gene mutation responsible for many if not the majority of canine TCCs is identical to the mutation behind many human bladder and urinary tract cancers.
Comparative oncology trials are underway, treatment regimens and drugs are the same or similar, and early phase drug clinical trials are often carried out on dogs.
But there’s a wealth of data already available and continually being generated. Until now, no one sought to aggregate existing data.
Be part of the effort.